AZD-1236

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAZD-1236
Drug Alias NameAZD-1236
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 9 inhibitorsMatrix metalloproteinase 12 inhibitors
TargetsMatrix metalloproteinase 12Matrix metalloproteinase 9
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaSlovakia +[13] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A